Breakthrough in Oncology: Novel ADC Rolditamig Deuderuxtecan Triples Progression-Free Survival in HER2-Low Breast Cancer

MADRID — In a landmark development for the treatment of metastatic breast cancer, researchers have unveiled results from the phase III APEX-Breast01 trial, demonstrating that the novel antibody-drug conjugate (ADC)…

New Antibody-Drug Conjugate Trastuzumab Rezetecan Shows Promise in HER2-Low Metastatic Breast Cancer

October 23, 2026 — In a significant development for oncology, researchers have unveiled compelling phase III trial data for trastuzumab rezetecan, an investigational antibody-drug conjugate (ADC) demonstrating substantial efficacy in…